Valeant Pharmaceuticals' third-quarter sales to rise

Mon Sep 29, 2014 9:28pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

(Reuters) - Valeant Pharmaceuticals International Inc's (VRX.TO: Quote) sales are expected to rise 15 percent in the third quarter but will face a tougher fourth-quarter comparison to year-ago results, Allergan Inc (AGN.N: Quote) said in a filing on Monday.

Allergan, the maker of Botox anti-wrinkle injections, has criticized Valeant's acquisition-based business model as it attempts to fend off the drugmaker's $51 billion hostile bid.

Valeant's third-quarter sales will reflect a weak year-ago period for contact lens maker Bausch & Lomb, which Valeant acquired for $8.7 billion in August 2013, according to the filing.

The Canadian company did not give a specific fourth-quarter forecast but said last week that it expects continued strong double-digit same store organic growth in the fourth quarter. Valeant announced that it will report third-quarter earnings on Oct. 20.

(Reporting by Susan Kelly in Chicago; Editing by Lisa Shumaker)

 
The head offices of Valeant Pharmaceuticals International Inc. are seen in Laval, Quebec May 20, 2014.   REUTERS/Christinne Muschi